Markets Canada Stocks Health Technology Pharmaceuticals: Major

CYBIN INC CYBN

CYBN

NEO

CYBN

CYBIN INC

NEO

See more on advanced chart See more on advanced chart

No trades

Upcoming Earnings

EPS

Market Cap

Div Yield

P/E

Upcoming Earnings

EPS

Market Cap

Div Yield

P/E

See more on advanced chart See more on advanced chart

Overview

News Ideas Financials Technicals Forecast

CYBN chart

Ideas

CYBN - Mushrooms; Nixon Delayed the Inevitable

CYBN

, 1WLong

hborou Updated

One of PSYK's holdings, young industry with a growing addressable market. Big pharma has not only failed to help humans who suffer depression, PTSD, drug abuse, etc. but in some ways made the situation worse. Psychedelics are widely misunderstood and I believe they can offer solutions under proper conditions and in a therapeutic manner. Barriers to entry is...

Cybin (CYBN) will be breaking a trend line in the next week

CYBN

, 1DLong

johnvee1111

They keep dropping news every few days and they've been one of the few in this sector that had a positive trend over this past summer, so carefully optimistic if would break the up trend in the next week, but will wait to see a clear breakout signal with increasing daily volume. Do you DD!

CYBIN on the watch list

CYBN

, 1DLong

johnvee1111

Keeping a close eye on CYBIN as it's been progressing nicely since March while the entire market has been pressured down. Will watch for a bounce on the lower trend with increasing volume and MACD reversal before adding more to my position (current position average of 1.36).

CYBN Day trade/swing trade potential.

CYBN

, 1DLong

tsx_trader Updated

US markets are closed, this may get some attention. Insane volume last Friday that drove the price higher. This would be a break out based trade. Im buying a break above 2.50 on a day trade basis, a trade which may turn into a swing trade if volume and movement is favourable.

CYBN.CA: Possible pennant forming, watching

CYBN

, 1DLong

LeLaf Premium

Watching this stock. Could form a pennent anytime now.

Technicals

Analyst rating

Financials

Valuation

Enterprise Value/EBITDA, TTM —

Enterprise Value, FQ —

Market Cap — Basic —

Number of Employees —

Number of Shareholders —

Price/Earnings, TTM —

Price/Revenue, TTM —

Price/Book Ratio, FY —

Price/Sales Ratio, FY —

Balance Sheet

Current Ratio, FQ —

Debt to Equity, FQ —

Net Debt, FQ —

Quick Ratio, FQ —

Total Assets, FQ —

Total Debt, FQ —

Operating Metrics

Return on Assets, TTM —

Return on Equity, TTM —

Return on Invested Capital, TTM —

Revenue per Employee, TTM —

Price History

Average Volume (10 day) —

Beta - 1 Year —

Price - 52 Week High —

Price - 52 Week Low —

Dividends

Dividends Paid, FY —

Dividends per Share, FY —

Expected Annual Dividends —

Dividends Yield —

Margins}

Net Margin, TTM —

Gross Margin, TTM —

Operating Margin, TTM —

Pretax Margin, TTM —

Income Statement

Basic EPS, Net Income —

Earnings per Share, Basic, TTM —

EBITDA, TTM —

Gross Profit, FY —

Last Annual EPS —

Last Annual Revenue, FY —

Net Income, FY —

Total Revenue, FY —

Free Cash Flow, TTM —

More financials

Profile

Sector: Health Technology

Industry: Pharmaceuticals: Major

Cybin, Inc. is an ethical biopharmaceutical company engaged in the development of therapeutics for patients to address a multitude of mental health issues. It is focused on progressing psychedelics to therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches, and treatment regimens for mental health disorders. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.